Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The <scp>DAPASALT</scp> trial
Dapagliflozin reduced blood pressure during standardised sodium intake in patients with type 2 diabetes and/or CKD without increasing sodium excretion, suggesting that the blood pressure-lowering effects occur through mechanisms beyond natriuresis.
Authors
- Rosalie A. Scholtes (ORCID: https://orcid.org/0000-0002-2794-2263)
- Niels Jongs (ORCID: https://orcid.org/0000-0002-0882-3656)
- Peter J. Greasley (ORCID: https://orcid.org/0000-0002-2529-4477)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Daniel Casillas
- Petter Bjornstad (ORCID: https://orcid.org/0000-0002-5160-2947)
- Jelle M. Beernink (ORCID: https://orcid.org/0000-0002-4615-9012)
- Charlotte M. Mosterd (ORCID: https://orcid.org/0000-0002-1309-5155)
- Vikas S. Sridhar (ORCID: https://orcid.org/0000-0001-7947-1822)
- Ann Hammarstedt
- Gozewijn D. Laverman (ORCID: https://orcid.org/0000-0002-8716-7115)
- Daniël H. van Raalte (ORCID: https://orcid.org/0000-0003-2894-6124)
- Cecilia Karlsson (ORCID: https://orcid.org/0000-0002-4299-8775)
- Marcel H.A. Muskiet (ORCID: https://orcid.org/0000-0003-4116-555X)
- Alyssa Caldwell‐McGee (ORCID: https://orcid.org/0009-0006-5944-7458)
- Lynette Driscoll
Institutions
- University Health Network (CA)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- University of Toronto (CA)
- University of Washington (US)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- Ziekenhuis Groep Twente (NL)
- Amsterdam University Medical Centers (NL)
- University of Colorado Denver (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1111/dom.16478
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- AstraZeneca